Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Tucatinib,Trastuzumab Emtansine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Tucatinib,Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucatinib,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tukysa (tucatinib) is a TKI of HER2, inhibiting phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed antitumor activity in HER2 expressing tumor cells in combination with trastu...
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Tucatinib,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucatinib,Oxaliplatin,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vivo (in living organisms), TUKYSA (tucatinib) inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either medicine alone...
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Tucatinib,Oxaliplatin,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucatinib,Oxaliplatin,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At a median duration of follow-up of 20.7 months, results of MOUNTAINEER trial showed a 38.1% cORR per blinded independent central review in HER2-positive patients who were assigned to receive Tuksya (tucatinib) in combination with trastuzumab.
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Tucatinib,Oxaliplatin,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients who received TUKYSA in combination with trastuzumab and capecitabine in the pivotal trial had a 46 percent reduction in the risk of cancer progression or death compared to patients who received trastuzumab and capecitabine alone.
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2021
Lead Product(s) : Tucatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucatinib,Capecitabine,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Details : Pivotal HER2CLIMB trial showed that TUKYSA resulted in a robust and durable prolongation of overall survival that was consistent with results from the primary analysis for HER2-positive metastatic breast cancer patients with brain metastases.
Product Name : Tukysa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Tucatinib,Capecitabine,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zanidatamab,Capecitabine,Tucatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric™ platform. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that e...
Product Name : ZW25
Product Type : Antibody
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Zanidatamab,Capecitabine,Tucatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zanidatamab,Capecitabine,Tucatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient with HER2-Ve+ Breast Cancer Dosed with Zanidatamab Tukysa Combo
Details : Zanidatamab binds to HER2 across a range of expression levels and has demonstrated multiple mechanisms of action including the formation of receptor clusters, resulting in receptor internalization and downregulation that affect signal transduction .
Product Name : ZW25
Product Type : Antibody
Upfront Cash : Inapplicable
July 28, 2021
Lead Product(s) : Zanidatamab,Capecitabine,Tucatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cinrebafusp Alpha,Tucatinib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Pieris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Pieris' option to co-develop and co-commercialize the second of 3 programs in the collaboration has been amended to provide it with a co-promotion option in the U.S, with Seagen solely responsible for the development and overall commercialization of that...
Product Name : PRS-343
Product Type : Protein
Upfront Cash : Undisclosed
March 25, 2021
Lead Product(s) : Cinrebafusp Alpha,Tucatinib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Pieris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration